Cancer immunotherapys are advancing into the esophageal cancer area one after another. According to related industries, Opdivo (Nivolumab) and MSD's Keytruda recently were added esophageal cancer indications in Korea. Opdivo obtained final approval from the MFDS last month and Keytruda on the 7th. With this permission, Opdivo can be prescribed as an auxiliary therapy for adult esophageal or GEJ cancer patients with residual pathological diseases after CRT.

The efficacy of this drug against esophageal cancer was confirmed through a phase III clinical CheckMate-577 study. As a result of the study, the median PFS period for patients treated with Opdivo after surgery was 22.4 months, twice as long as 11 mon